Compare Ascendis Pharma A/S (ASND) vs iShares Core MSCI Emerging Markets ETF (IEMG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs iShares Core MSCI Emerging Markets ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while iShares Core MSCI Emerging Markets ETF trades at $79.16. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, iShares Core MSCI Emerging Markets ETF nearer its low. Which is the better fit depends on your goals.
| ASND | IEMG | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $277.18 | $86.00 |
52-Week Low | $163.32 | $59.90 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
IEMG trades at $81.33, up 0.38% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF has surged 35% over the past year, driven by strong inflows into emerging markets and a 40% technology weighting, particularly in South Korean and Taiwanese AI-related stocks. Recent news highlights record capital flows and outperformance versus developed markets, though volatility remains elevated.
Outlook is mixed: attractive valuations and AI exposure offer growth potential, but concentration risk and geopolitical tensions pose headwinds. Investors face trade-offs between higher returns and increased volatility, with analyst sentiment cautious due to recent price gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →
